ES2513569T3 - Formulación de liberación prolongada que comprende un derivado de metastina - Google Patents

Formulación de liberación prolongada que comprende un derivado de metastina Download PDF

Info

Publication number
ES2513569T3
ES2513569T3 ES11731522.6T ES11731522T ES2513569T3 ES 2513569 T3 ES2513569 T3 ES 2513569T3 ES 11731522 T ES11731522 T ES 11731522T ES 2513569 T3 ES2513569 T3 ES 2513569T3
Authority
ES
Spain
Prior art keywords
release formulation
prolonged release
lactic acid
metastin derivative
polymer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11731522.6T
Other languages
English (en)
Inventor
Tomomichi Futo
Hikaru Taira
Seitaro Mizukami
Naoyuki Murata
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44583663&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2513569(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2513569T3 publication Critical patent/ES2513569T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J3/00—Processes of treating or compounding macromolecular substances
    • C08J3/005—Processes for mixing polymers
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L67/00—Compositions of polyesters obtained by reactions forming a carboxylic ester link in the main chain; Compositions of derivatives of such polymers
    • C08L67/04—Polyesters derived from hydroxycarboxylic acids, e.g. lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J2367/00—Characterised by the use of polyesters obtained by reactions forming a carboxylic ester link in the main chain; Derivatives of such polymers
    • C08J2367/04—Polyesters derived from hydroxy carboxylic acids, e.g. lactones
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J2389/00—Characterised by the use of proteins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L89/00—Compositions of proteins; Compositions of derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Una formulación de liberación prolongada que comprende un compuesto representado por la fórmula: Ac-D-Tyr-Hyp-Asn-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 o una de sus sales, y un polímero de ácido láctico que tiene un peso molecular medio ponderal de aproximadamente 5.000 a aproximadamente 40.000 o una de sus sales, en donde el polímero de ácido láctico es un polímero que consiste en ácido láctico solo.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14
imagen15
imagen16

Claims (1)

  1. imagen1
ES11731522.6T 2010-06-25 2011-06-23 Formulación de liberación prolongada que comprende un derivado de metastina Active ES2513569T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2010144792 2010-06-25
JP2010144792 2010-06-25
PCT/JP2011/064992 WO2011162413A1 (en) 2010-06-25 2011-06-23 Sustained-release formulation

Publications (1)

Publication Number Publication Date
ES2513569T3 true ES2513569T3 (es) 2014-10-27

Family

ID=44583663

Family Applications (1)

Application Number Title Priority Date Filing Date
ES11731522.6T Active ES2513569T3 (es) 2010-06-25 2011-06-23 Formulación de liberación prolongada que comprende un derivado de metastina

Country Status (24)

Country Link
US (2) US20130210742A1 (es)
EP (1) EP2585091B1 (es)
JP (1) JP5838173B2 (es)
KR (1) KR20130097088A (es)
CN (1) CN103025343B (es)
AR (1) AR081980A1 (es)
AU (1) AU2011270093A1 (es)
BR (1) BR112012032544A2 (es)
CA (1) CA2802209C (es)
CL (1) CL2012003645A1 (es)
CR (1) CR20120604A (es)
DO (1) DOP2012000304A (es)
EA (1) EA021663B1 (es)
EC (1) ECSP12012350A (es)
ES (1) ES2513569T3 (es)
IL (1) IL223266A0 (es)
MA (1) MA34321B1 (es)
MX (1) MX2012014265A (es)
PE (1) PE20130276A1 (es)
SG (1) SG186070A1 (es)
TN (1) TN2012000562A1 (es)
TW (1) TW201204378A (es)
UY (1) UY33465A (es)
WO (1) WO2011162413A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016020901A1 (en) 2014-08-07 2016-02-11 Acerta Pharma B.V. Methods of treating cancers, immune and autoimmune diseases, and inflammatory diseases based on btk occupancy and btk resynthesis rate
EP3518952A1 (en) 2016-09-30 2019-08-07 Myovant Sciences GmbH Methods of treating female infertility

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9211268D0 (en) * 1992-05-28 1992-07-15 Ici Plc Salts of basic peptides with carboxyterminated polyesters
FR2693905B1 (fr) * 1992-07-27 1994-09-02 Rhone Merieux Procédé de préparation de microsphères pour la libération prolongée de l'hormone LHRH et ses analogues, microsphères et formulations obtenues.
AR023940A1 (es) * 2000-05-03 2002-09-04 Eriochem Sa Procedimiento para la produccion de microcapsulas de liberacion prolongada de peptidos solubles en agua
CN1269870C (zh) * 2000-08-07 2006-08-16 和光纯药工业株式会社 乳酸聚合物及其制备方法
WO2002085399A1 (en) * 2001-04-20 2002-10-31 Takeda Chemical Industries, Ltd. Peptide-containing preparations
JP2003002841A (ja) * 2001-04-20 2003-01-08 Takeda Chem Ind Ltd ペプチド含有製剤
TW200529890A (en) * 2004-02-10 2005-09-16 Takeda Pharmaceutical Sustained-release preparations
US8404643B2 (en) * 2005-12-22 2013-03-26 Takeda Pharmaceutical Company Limited Metastin derivatives and use thereof
AR058584A1 (es) * 2005-12-22 2008-02-13 Takeda Pharmaceutical Derivados de metastina y uso de los mismos
CN101341168B (zh) * 2005-12-22 2013-01-16 武田药品工业株式会社 肿瘤迁移抑制素衍生物及其用途
JO3048B1 (ar) * 2006-10-25 2016-09-05 Takeda Pharmaceuticals Co مشتقات متاستين واستخدامها
CN101528772B (zh) * 2006-10-25 2013-03-13 武田药品工业株式会社 Metastin衍生物及其用途
BRPI0720582B1 (pt) * 2006-12-18 2021-08-24 Takeda Pharmaceutical Company Limited Composição de liberação prolongada, processo para a preparação da mesma, composição farmacêutica, agente profilático ou terapêutico, e, uso de uma substância fisiologicamente ativa
US20110118172A1 (en) * 2008-04-24 2011-05-19 Takeda Pharmaceutical Company Limited Metastin derivative and use thereof
WO2010076896A1 (en) * 2008-12-29 2010-07-08 Takeda Pharmaceutical Company Limited Prophylactic/therapeutic agent for cancer
MA33910B1 (fr) * 2009-12-22 2013-01-02 Takeda Pharmaceutcal Company Ltd Formulation à libération prolongée

Also Published As

Publication number Publication date
CL2012003645A1 (es) 2013-04-05
CA2802209A1 (en) 2011-12-29
AU2011270093A1 (en) 2013-01-10
CN103025343B (zh) 2015-03-25
WO2011162413A1 (en) 2011-12-29
EP2585091B1 (en) 2014-09-10
CN103025343A (zh) 2013-04-03
CA2802209C (en) 2019-12-31
UY33465A (es) 2012-01-31
TW201204378A (en) 2012-02-01
EA201291303A1 (ru) 2013-04-30
SG186070A1 (en) 2013-01-30
ECSP12012350A (es) 2014-02-28
EP2585091A1 (en) 2013-05-01
US20180243422A1 (en) 2018-08-30
AR081980A1 (es) 2012-10-31
KR20130097088A (ko) 2013-09-02
JP2013530926A (ja) 2013-08-01
IL223266A0 (en) 2013-02-03
JP5838173B2 (ja) 2016-01-06
CR20120604A (es) 2013-03-21
MA34321B1 (fr) 2013-06-01
BR112012032544A2 (pt) 2016-10-11
PE20130276A1 (es) 2013-03-20
MX2012014265A (es) 2013-01-18
US20130210742A1 (en) 2013-08-15
EA021663B1 (ru) 2015-08-31
TN2012000562A1 (en) 2014-04-01
DOP2012000304A (es) 2013-01-31

Similar Documents

Publication Publication Date Title
CY1119784T1 (el) Ακετυλιωμενες σαλικυλικες ενωσεις λιπαρου οξεος και οι χρησεις αυτων
ES2525481T3 (es) Derivados espirocíclicos de ácido tetrónico
ME01284B (me) Organska jedinjenja
CR20110354A (es) Compuestos de amidina sustituidas para combatir plagas de animales
UY31940A (es) Derivados sustituido del 4,5-(sustituido-piridin-3-il)-1-metil-1h-indol, sus sales farmacéuticamente aceptables, polimorfos, rotámeros, pro-fármacos, anantiómeros, hidratos, solvatos del mismo, composiciones conteniéndolos y aplicaciones
CY1115043T1 (el) Φαρμακευτικο σκευασμα
RS53003B (en) C7-FLUORO SUBSTITUTED TETRACYCLINE UNITS
DOP2011000196A (es) Compuestos purina
CR20110219A (es) Ácidos naftilacéticos
RU2012148909A (ru) Новый синтез соединений тиазолидиндиона
ECSP11011224A (es) Derivados de tiadiazoles y oxadiazoles, su preparaciòn y su aplicaciòn en terapia
RU2009101579A (ru) Мономер для поликонденсации
ES2513569T3 (es) Formulación de liberación prolongada que comprende un derivado de metastina
EA201071424A1 (ru) Сульфонатные соли 2-амино-3-карбэтоксиамино-6-(4-фторбензиламино)пиридина
BR112012029954A2 (pt) composto de poliamida
RU2008151868A (ru) Мономер для поликонденсации
UY34916A (es) "preparación sólida que contiene ácido[(3s)-6-){2´,6´-dimetil-4´-[3-(metilsulfonil)propoxi]bifenil-3-il}metoxi)-2,3-dihidro-1-benzofuran-3-il]acético"
UY32247A (es) Nuevos compuestos de aminociclohexilo, composiciones farmacéuticas de los mismos y aplicaciones
CR20120290A (es) Formulaciòn de liberaciòn sostenida
ES2585558T3 (es) Uso de sales de 3-carboxi-N-etil-N,N-dimetilpropan-1-aminio en el tratamiento de una enfermedad cardiovascular
ES2571435T3 (es) Composiciones de nanopartículas que contienen polímeros e insecticidas de diamida de ácido antranílico para recubrimiento de propágulos
ES2599609T3 (es) Fotoiniciadores copolimerizables
ES2526147T3 (es) Ésteres de metronidazol para el tratamiento de la rosácea
RS53747B1 (en) FENANTRENON UNITS, COMPOSITIONS AND METHODS
ES2504540T3 (es) Composición para aplicación cutánea externa